Rob Dillard

DocwireNews

Renal dysfunction, especially chronic kidney disease (CKD), increases the risk of major adverse cardiovascular events (MACEs) in patients with type 2 diabetes mellitus (T2DM), <a href="https://pubmed.ncbi.nlm.nih.gov/39377142/" target="_blank" rel="noopener">according to</a> a study published in Acta Cardiologica.
Researchers assessed renal function and outcomes in 505 diabetic patients undergoing percutaneous coronary intervention  (PCI). The population of interest were stratified using glomerular filtration rate (GFR). Logistic regression and receiver operating characteristic (ROC) analysis were used to analyze the associations and predictive capabilities.
According to the results, there were notable differences regarding age, creatinine levels, and number of culprit vessels between diabetics with and without CKD. The researchers found that severe CKD was associated with higher odds of mortality at one month (OR: 15.694, p value &lt;.001), one-month MACE (OR: 7.734, p value &lt;.001), and TVD (OR: 3.740, p value &lt;.001). Patients with severe CKD also had significantly higher odds of six-months mortality (OR: 12.192, p value &lt;.001) and 6-months MACE (OR: 3.848, p value: .001). Moreover, the researchers noted that GFR demonstrated notable predictive accuracy for mortality at one- and six-months follow-up (AUC: 0.77 and 0.71, respectively).
&#8220;Renal dysfunction, particularly severe CKD, significantly elevates risks of MACE, mortality, and TVD. Strategies to optimize renal function and tailor cardiovascular management could mitigate adverse outcomes in this high-risk population,&#8221; the researchers concluded.
&nbsp;
&nbsp;

Jamie L. Studts, PhD

Cecilia Brown

Focusing on People: Dr. Studts Discusses Quality Implementation of Lung Cancer Screening Program

WCLC 2024

Study Finds Challenges Faced by People Living With Diabetes, HIV

Diabetes

Renal Dysfunction is a Predictor of Adverse Cardiovascular Outcomes in Patients With Diabetes

Latest News

Renal dysfunction increases the risk of MACEs in patients with type 2 diabetes mellitus.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe